It has been a volatile year for the biotech.

BioNTech reported topline Phase 2/3 results from the AHEAD-MERIT trial, where BNT113 plus pembrolizumab did not show a ...

Wall Street is quite bullish on BioNTech. In fact, among the 20 analysts covering it, 13 rate the stock a strong buy, while ...

Is bigger always better? Not necessarily.

Detailed price information for Bank of Montreal (BMO-N) from The Globe and Mail including charting and trades.

Profit taking is hitting one of biotech’s hottest trades, and the selling is landing heaviest on the stock that ran the ...

Healthcare is drawing fresh buying as money moves away from the market’s popular technology trade, and one messenger RNA (mRNA) name is pulling well ahead of the pack. Moderna (NASDAQ:MRNA | MRNA ...

BioNTech has scheduled its next results for November 3, 2026, according to MetaCap. The date gives investors a fixed point ...

BioNTech has seen its share price slide over recent years while the business reshapes itself beyond the COVID-19 vaccine boom ...

BioNTech pivots from Covid windfall to oncology with 33 trials and $19B cash; key pumitamig data post-2028. Click for more on BNTX stock.

BioNTech's latest reported quarter was Q2 2026. MarketBeat said revenue fell 59.5 percent year over year to USD 122.31 million, while the company posted an adjusted EPS loss of USD 2.53 against a USD ...

BioNTech SE (BNTX), the Mainz, Germany-headquartered pharmaceutical company that co-developed the messenger RNA-based COVID vaccine, Comirnaty, alongside Pfizer (PFE), during the pandemic, announced ...